A meta-analysis investigated the correlation between CD133+ gastric cancers and clinical outcomes in 773 patients, identifying worse accumulative 5 year OS rates in CD133+ patients (21.4%) as compared with CD133− patients (55.7%), in addition to a close correlation between CD133 over-expression and adverse clinicopathological features (Wen et al., 2013). Here, PROM1 is linked to gastric cancer.